Summary
This 8-K filing from Edwards Lifesciences Corporation (EW) on April 24, 2012, primarily announces the company's financial results for the first quarter of 2012. The report itself is brief, serving as a cover for a press release (Exhibit 99.1) that contains the detailed financial information. Investors should review the accompanying press release for specifics on revenue, earnings, and any forward-looking guidance provided for the first quarter of 2012. While the 8-K does not contain the actual financial figures, it signifies the formal reporting of these results to the SEC. The key takeaway for investors is the availability of the Q1 2012 financial performance data, which is crucial for assessing the company's operational health, profitability, and overall financial condition during that period. Shareholders and potential investors are directed to Exhibit 99.1 for a comprehensive understanding of the company's performance.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on April 24, 2012, to report its financial results for the first quarter of 2012.
- 2The 8-K filing incorporates by reference a press release (Exhibit 99.1) containing the detailed Q1 2012 financial results.
- 3Investors are directed to the press release for specific financial data, including revenue and earnings for the first quarter.
- 4The filing officially marks the public disclosure of EW's Q1 2012 financial performance.
- 5The information furnished under Item 2.02 is not deemed 'filed' for the purposes of the Securities Exchange Act of 1934.
- 6The report was signed by Thomas M. Abate, Corporate Vice President and Chief Financial Officer.